1. 316TiPNeoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study. (24th November 2019) Authors: Cohen, E; Uppaluri, R; Lee, N; Westra, W; Haddad, R; Temam, S; Le Tourneau, C; Chernock, R; Safina, S; Tao, Y; Klochikhin, A; Meirovitz, A; Brana, I; Ge, J Y; Swaby, R; Bidadi, B; Adkins, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗